drugset / Trial / NCT01500980

Malaria Challenge in Healthy Volunteers

NCT01500980

Phase 1 Completed 36 enrolled Seattle Children's Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine if sterile, protective immunity to malaria can be induced by malaria parasite exposure limited to the early liver stage of the parasite lifecycle.

Timeline

Start
2011-12
Primary completion
2012-07
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Chloroquine Small molecule 300 mg
Subject Primaquine Small molecule 45 mg